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AbstrACt
background Patients with advanced rare cancers 
have poor prognosis and few treatment options. As 
immunotherapy is effective across multiple cancer types, 
we aimed to assess pembrolizumab (programmed cell 
death 1 (PD-1) inhibitor) in patients with advanced rare 
cancers.
Methods In this open- label, phase 2 trial, patients with 
advanced rare cancers whose tumors had progressed 
on standard therapies, if available, within the previous 
6 months were enrolled in nine tumor- specific cohorts and 
a 10th cohort for other rare histologies. Pembrolizumab 
200 mg was administered intravenously every 21 days. 
The primary endpoint was non- progression rate (NPR) 
at 27 weeks; secondary endpoints were safety and 
tolerability, objective response rate (ORR), and clinical 
benefit rate (CBR).
results A total of 127 patients treated between August 
15, 2016 and July 27, 2018 were included in this analysis. 
At the time of data cut- off, the NPR at 27 weeks was 28% 
(95% CI, 19% to 37%). A confirmed objective response 
(OR) was seen in 15 of 110 (14%) evaluable patients 
(complete response in one and partial response in 14). 
CBR, defined as the percentage of patients with an OR or 
stable disease ≥4 months, was 38% (n=42). Treatment 
was ongoing in 11 of 15 patients with OR at last follow- 
up. In the cohort with squamous cell carcinoma (SCC) 
of the skin, the NPR at 27 weeks was 36%, ORR 31%, 
and CBR 38%. In patients with adrenocortical carcinoma 
(ACC), NPR at 27 weeks was 31%, ORR 15%, and CBR 
54%. In the patients with carcinoma of unknown primary 
(CUP), NPR at 27 weeks was 33%, ORR 23%, and CBR 
54%. In the paraganglioma–pheochromocytoma cohort, 
NPR at 27 weeks was 43%, ORR 0%, and CBR 75%. 
Treatment- related adverse events (TRAEs) occurred in 66 
of 127 (52%) patients, and 12 (9%) had grade ≥3 TRAEs. 
The most common TRAEs were fatigue (n=25) and rash 
(n=17). There were six deaths, all of which were unrelated 
to the study drug.
Conclusions The favorable toxicity profile and antitumor 
activity seen in patients with SCC of skin, ACC, CUP, and 
paraganglioma–pheochromocytoma supports further 
evaluation of pembrolizumab in this patient population.
trial registration number NCT02721732
IntroduCtIon
Rare cancers pose many challenges. In the 
absence of a universal definition,1 the Amer-
ican Cancer Society has defined rare cancers 
as those with an incidence of fewer than six 
cases per 100,000 people per year.2 3 Although 
they are individually uncommon, rare 
cancers are a major public health problem, 
as they collectively accounted for 13% of all 
new cancer diagnoses and 25% of all cancer- 
related deaths in adults in 2017 in the USA.3 
The prognosis for patients with advanced 
rare cancer is poor; the 5- year survival rate 
for these cancers is 15%–20% lower than for 
more common cancers.4 The poor outcomes 
associated with rare cancers have been 
attributed to difficulty or delay in diagnosis, 
limited access to centers with expertise, and 
limited therapeutic options.4 Despite the 
significant burden and aggressive nature of 
these diseases, research initiatives that could 
lead to the development and approval of new 
therapies for rare cancers are few. Thus, there 
is a compelling and urgent need to identify 
novel therapeutic strategies to improve treat-
ment outcomes in this patient population.
In recent years, the seminal discovery of 
immune checkpoint inhibitors have revo-
lutionized treatment of cancer.5 6 Pembroli-
zumab is a humanized IgG4κ monoclonal 
antibody that targets the programmed cell 
death (PD-1)/programmed cell death ligand 
1 (PD- L1) pathway, which is often hijacked by 
tumor cells to escape immune surveillance. 
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On the basis of durable objective responses and a favor-
able safety profile, pembrolizumab has been approved 
by the US Food and Drug Administration (FDA) for 
the treatment of several tumor types.7 Accumulating 
evidence indicates that pembrolizumab produces durable 
responses in a tumor- agnostic fashion, as it targets the 
immune system rather than the tumor itself. Recently, 
the FDA provided its first tissue- agnostic/site- agnostic 
drug approval—for pembrolizumab in patients with 
unresectable or metastatic microsatellite instability—
high or mismatch repair deficient solid tumors.8 This 
approval suggests that pembrolizumab may have thera-
peutic potential in patients with advanced rare cancers. 
However, the efficacy and the safety profile of the drug 
in rare cancers are unknown. To address this critical, 
unmet clinical need and overcome the challenges asso-
ciated with the rarity of these cancers, we designed an 
open- label, investigator- initiated, phase 2 basket study of 
pembrolizumab in patients with advanced rare cancers. As 
enrolling patients with advanced rare cancers remains a 
challenge, we chose to publish the findings from the four 
tumor- specific cohorts (squamous cell carcinoma (SCC) 
of the skin, adrenocortical carcinoma (ACC), carcinoma 
of unknown primary (CUP), and paraganglioma–pheo-
chromocytoma) that met the protocol- specified criteria 
for interim analysis rather than to wait for completion of 
enrollment in all the 10 cohorts.
Methods
study design and patients
Patients enrolled in the study from August 15, 2016, to 
July 27, 2018 (cut- off date) were included in this analysis. 
Eligible patients were adults 18 years and older, with histo-
logically confirmed advanced rare cancers, whose disease 
had progressed while on standard therapies (if available) 
within the previous 6 months. Patients had to have measur-
able disease according to Response Evaluation Criteria 
in Solid Tumors (RECIST) V.1.19 or immune- related 
RECIST (irRECIST),10 except for cohorts 9 and 10, in 
which patients could have evaluable disease. Additional 
inclusion criteria were an Eastern Cooperative Oncology 
Group performance status of 0 or 111 and adequate organ 
and bone marrow function. Patients previously treated 
with an anti- PD-1, anti- programmed cell death ligand 
(PD- L)1, or anti- PD- L2 agent were excluded from this 
study. A full list of inclusion and exclusion criteria is in 
the online supplementary file (eMethods).
Patients were enrolled in ten cohorts: (1) SCC of the 
skin, (2) anaplastic thyroid carcinoma, later revised to 
small cell malignancies of non- pulmonary origin, (3) 
ACC, (4) medullary renal cell carcinoma, (5) CUP, (6) 
penile carcinoma, (7) thymic carcinoma, later revised to 
vascular sarcoma, (8) testicular cancer, later relabeled 
as germ cell tumor, (9) paraganglioma–pheochromocy-
toma, and (10) other rare tumor histologies (excluding 
tumor types included in NCT02054806). As no patients 
were enrolled in the anaplastic thyroid carcinoma (cohort 
2) and thymic carcinoma (cohort 7) cohorts in the first 9 
months of the study, the protocol was revised to change 
these cohorts to include small cell malignancies of non- 
pulmonary origin and vascular sarcoma, respectively. 
The testicular cancer cohort (cohort 8) was relabeled as 
the germ cell tumor cohort to include germ cell tumors 
arising not only in the testicles but also in other locations.
Procedures
All patients received 200 mg of pembrolizumab intra-
venously every 3 weeks. Treatment continued until 
documented disease progression, unacceptable adverse 
event(s), investigator’s decision to stop treatment, with-
drawal of consent, or completion of 24 months of treat-
ment with pembrolizumab. Patients who had radiographic 
progression but were clinically stable were allowed to 
continue pembrolizumab until progressive disease (PD) 
was confirmed by imaging at least 4 weeks after the first 
PD assessment. Patients who had a confirmed complete 
response (CR) could discontinue pembrolizumab after 
receiving at least 27 weeks of treatment. No dose modi-
fications were allowed, but in the event of adverse events 
dose delays were permitted.
Tumor imaging was performed at baseline and every 
9 weeks for the first 6 months of treatment and every 12 
weeks thereafter at the discretion of treating physician 
if patients had had CR, partial response (PR), or stable 
disease (SD) for more than 27 weeks. irRECIST was 
applied to direct clinical management and to report the 
interim results of this study. Response to treatment was 
also assessed using RECIST V.1.1 to capture the atypical 
responses observed in patients treated with immunother-
apeutic agents. Objective response (OR), defined as irCR 
or irPR was confirmed by a repeat radiographic assess-
ment at least 4 weeks after the criteria for OR were first 
met.
The adverse events were graded according to the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events V.4.03.12
Biomarker analysis was performed on fresh tissue 
sample obtained at baseline or an archival tissue sample. 
The PD- L1 characterization of baseline tumor samples by 
immunohistochemistry was performed at a central labora-
tory on formalin- fixed, paraffin- embedded tissue sections 
using Merck 22C3 antibody. Based on the percentage and 
intensity of membrane staining, an H- score ranging from 
0 to 300 was assigned. By using recursive partitioning 
analysis, a score of 42·5 was identified as the optimal cut- 
off point for PD- L1 H- score. Tumor infiltrating lympho-
cytes (TILs) within tumor nests were scored on a scale 
from 0 to 3: 0 for absence of TILs, 1 for a few TILs, 2 for a 
moderate amount of TILs, and 3 for intense intratumoral 
lymphocytic infiltration.
outcomes
The primary endpoint was non- progression rate (NPR) 
at 27 weeks, defined as the proportion of patients who 
were alive and progression free at 27 weeks as assessed by 
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Table 1 Characteristics of 127 patients with advanced rare 
cancers treated with pembrolizumab
All patients
(n=127)
Age at enrollment, years
  Median (range) 56 (22–84)
Sex, n (%)
  Male 68 (54)
  Female 59 (46)
ECOG performance status, n (%)
  0 15 (12)
  1 112 (88)
Number of prior therapies, n (%)
  ≤2 78 (61)
  >2 49 (39)
Cohort, n
  (1) Squamous cell carcinoma of the skin 19
  (2) Small cell malignancies of non- 
pulmonary origin
11
  (3) Adrenocortical carcinoma 15
  (4) Medullary renal cell carcinoma 4
  (5) Carcinoma of unknown primary 22
  (6) Penile carcinoma 3
  (7) Vascular sarcoma 7
  (8) Germ cell tumor 12
  (9) Paraganglioma–pheochromocytoma 9
  (10) Other rare tumors 25
PD- L1 status, n (%)*
  Positive (H- score >42.5) 21 (20)
  Negative (H- score ≤42.5) 84 (80)
Tumor- infiltrating lymphocyte score, n (%)*
  0 5 (5)
  1 47 (45)
  2 25 (24)
  3 28 (27)
*PD- L1 staining and tumor- infiltrating lymphocytes were assessed 
in 105 baseline tissue samples.
ECOG, Eastern Cooperative Oncology Group; PD- L1, programmed 
cell death ligand 1.
irRECIST. The secondary endpoints were safety and toler-
ability of pembrolizumab; objective response rate (ORR), 
defined as the percentage of patients with irCR or irPR; 
clinical benefit rate (CBR), defined as the percentage of 
patients with irCR, irPR, or irSD ≥4 months; and associa-
tion of NPR at 27 weeks and baseline PD- L1 status. The 
exploratory objective was evaluation of the potential of 
TILs as a predictor of therapy effectiveness. As the study 
remains open, the final response rates may change with 
additional follow- up.
statistical analysis
We used Simon’s optimal two- stage design,13 developed 
by one of the co- authors (RMS), for each of the nine 
tumor- specific cohorts. At least three of the first 12 
treated patients had to be alive and progression free at 27 
weeks before an additional 13 patients were enrolled. The 
null success rate was set at 20% and the alternative rate at 
40% for each cohort. This design has a 10% Type I error 
rate, 82% power, and 56% probability of stopping after 
the first stage if the true 27- week progression- free survival 
rate is 20%. Because the tenth cohort was made up of a 
heterogeneous mix of rare tumors, the protocol dictated 
that at least 25 eligible patients would be enrolled. If a 
positive outcome (alive and progression free at 27 weeks) 
was observed in a tumor type, that tumor type would be 
expanded to include an additional 14 patients. With 14 
patients, the exact 95% CI for the success rate will have 
half- width no larger than 0.27.
Clinical efficacy was measured by NPR at 27 weeks. 
Patients who discontinued the study before 27 weeks for 
reasons other than disease progression or death were 
considered non- evaluable for assessment of the primary 
efficacy endpoint. The best overall response was defined 
as the best response observed from the start of the treat-
ment until disease progression or discontinuation of 
treatment for any reason. A waterfall plot was used to 
illustrate the maximum percentage of change in tumor 
measurements from baseline per irRECIST. All patients 
who received at least one dose of pembrolizumab were 
included in safety analysis. The Pearson χ2 test was used 
to assess the association between NPR at 27 weeks and 
baseline PD- L1 expression and TIL scores.
Futility interim analyses were planned for each of the 
tumor- specific cohorts (cohorts 1–9) after the first 12 
evaluable patients enrolled in that cohort had 27- week 
data available to assess NPR at 27 weeks or when there 
were three or more responders in a cohort, even when 
fewer than 12 patients were enrolled.
results
A total of 128 patients with advanced rare cancers were 
enrolled between August 15, 2016 and July 27, 2018. One 
patient enrolled in the ACC cohort was excluded from 
the study due to change in the diagnosis. Therefore, 127 
patients were included in this analysis. The numbers of 
patients enrolled in each of the ten cohorts at the time of 
data cut- off and baseline patient characteristics are shown 
in table 1.
The primary endpoint, NPR at 27 weeks assessed by 
irRECIST in 105 patients with advanced rare cancer, 
was 28% (29 patients; 95% CI, 19% to 37%). NPR at 27 
weeks was not assessed in nine patients who had come 
off treatment prior to 27 weeks due to withdrawal of 
consent (n=5), patient/investigator choice (n=2), or 
toxicity (n=2) and in 13 active patients who had not 
reached week 27 on treatment by the cut- off date. Of the 
127 patients, 110 patients were evaluable for response by 
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Table 2 Response to treatment with pembrolizumab as assessed by irRECIST in four tumor- specific cohorts
SCC of the skin ACC CUP P–P
Number of patients treated 19 15 22 9
Number of patients assessed for NPR at 27 weeks (%) 14 (74) 13 (87) 12 (55) 7 (78)
NPR at 27 weeks (%) 5 (36) 4 (31) 4 (33) 3 (43)
Number of patients assessed for ORR and CBR (%) 16 (84) 13 (87) 13 (59) 8 (89)
  Complete response, n (%) 1 (6) 0 (0) 0 (0) 0 (0)
  Partial response, n (%) 4 (25) 2 (15) 3 (23) 0 (0)
  Stable disease, n (%) 2 (13)* 6 (46)* 4 (31) 6 (75)
  Progressive disease, n (%) 9 (56) 5 (38) 6 (46) 2 (25)
ORR, n (%) 5 (31) 2 (15) 3 (23) 0 (0)
CBR, n (%) 6 (38) 7 (54) 7 (54) 6 (75)
*One patient in each group had stable disease <4 months and was thus not included in the calculation of CBR.
ACC, adrenocortical carcinoma; CBR, clinical benefit rate; CUP, carcinoma of unknown primary; irRECIST, immune- related Response 
Evaluation Criteria in Solid Tumors; NPR, non- progression rate; ORR, objective response rate; P–P, paraganglioma–pheochromocytoma; SCC, 
squamous cell carcinoma.
irRECIST. Seventeen patients were not evaluable as they 
had either not reached the time of first restaging (n=10) 
or had come off treatment prior to first restaging due to 
withdrawal of consent (n=4), patient/investigator choice 
(n=2), or toxicity (n=1). Four of the 110 patients did not 
have measurable disease. Two of them were in cohort 10, 
which allowed for patients with evaluable disease. The 
remaining two patients with SCC and CUP who were 
initially said to have measurable disease were found to have 
evaluable disease on review. However, they were included 
in the analysis, as they were followed for response using 
non- target lesions. Fifteen of the 110 patients had OR 
(one had irCR and 14 had irPR), representing an ORR 
of 14% (95% CI, 8% to 21%). An additional 27 (25%) 
patients had SD ≥4 months, representing a CBR of 38% 
(n=42; 95% CI, 29% to 48%). All the patients with OR 
had remained on the study for at least 8 months (range, 
8·1 to 23·5 months), with 11 of them (73%) continuing 
on the study at last follow- up.
The pre- specified criteria for interim analyses were 
met in four tumor- specific cohorts: cohort 1 (SCC of 
the skin), cohort 3 (ACC), cohort 5 (CUP), and cohort 
9 (paraganglioma–pheochromocytoma) (table 2). The 
best overall responses of the evaluable patients are illus-
trated in figure 1. Percentage changes in tumor measure-
ments from baseline during the course of treatment with 
pembrolizumab is shown in figure 2. Thirteen additional 
patients will be enrolled in each of the four cohorts as the 
criteria for non- futility was met.
In the cohort of patients with SCC of the skin, 19 
patients received at least one dose of pembrolizumab. 
The NPR at 27 weeks was 36% (5 of 14 evaluable patients; 
95% CI, 13% to 65%). Sixteen patients were evaluable for 
response. Three patients were not evaluable for response 
as two patients came off treatment prior to first restaging 
due to withdrawal of consent and patient choice. The 
third patient had not reached the 9- week response 
assessment period. One patient had irCR and four had 
irPR, for an ORR of 31% (95% CI, 11% to 59%). In addi-
tion, one of two patients with irSD had disease control for 
≥4 months, representing a CBR of 38% (95% CI, 15% to 
65%). At the time of data cut- off, four of the five patients 
with OR had an ongoing response, at 15·9, 17·3, 20·1, and 
23·4 months since treatment initiation. Despite a 100% 
decrease in target lesions, two patients were assessed as 
irPR as irCR could not be confirmed at the time of data 
cut- off in one patient and presence of non- target lesions 
precluded the assignment of irCR in the other patient. 
Two other patients with unconfirmed irPR were assessed 
to have irSD as one patient withdrew consent from the 
study and the other patient had come off the study due to 
toxicity just prior to the date of data cut- off.
In the cohort of patients with ACC, 15 patients received 
at least one dose of pembrolizumab. The NPR at 27 weeks 
was 31% (four of 13 evaluable patients; 95% CI, 9% to 
61%). Of the 15 patients, two were not evaluable for 
response as they came off treatment prior to first restaging 
due to toxicity and principal investigator (PI) choice. Two 
of the 13 patients evaluable for response had irPR for an 
ORR of 15% (95% CI, 2% to 45%). In addition, five of 
six patients with irSD had disease control for ≥4 months, 
representing a CBR of 54% (95% CI, 25% to 81%). Of 
the two patients with an OR, one was still continuing 
treatment at 23·5 months since treatment initiation.
In the cohort of patients with CUP, 22 patients received 
at least one dose of pembrolizumab. The NPR at 27 weeks 
was 33% (four of 12 evaluable patients; 95% CI, 10% to 
65%). Of the 22 patients, nine were not evaluable for 
response as two patients came off treatment prior to first 
restaging due to withdrawal of consent and seven patients 
had not reached the 9- week response assessment period. 
Of the 13 patients evaluable for response, three had irPR, 
for an ORR of 23% (95% CI, 5% to 54%), and all three 
patients had ongoing responses, at 16·7, 17·6, and 21·3 
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Figure 1 Radiological response to pembrolizumab treatment. The figure illustrates the best overall response to pembrolizumab 
treatment using the immune- related Response Evaluation Criteria in Solid Tumors (irRECIST) in four tumor- specific cohorts. The 
values shown are the maximum percentage change from baseline in the sum of the longest diameters of all target lesions and 
any new lesions in patients receiving pembrolizumab. Each bar represents a patient. Five of six patients who derived benefit 
from continuing on the treatment after an initial assessment of PD by RECIST V.1.1 (pseudoprogression) are represented in the 
figure. The sixth patient who had pseudoprogression was enrolled in 10th cohort (not shown). Patients with clinical progression 
of disease were arbitrarily assigned 20% increase in tumor burden. The dashed line indicates the 30% reduction in tumor 
burden that is consistent with an objective response to treatment according to irRECIST. In squamous cell carcinoma of skin 
cohort, response data is not shown for three of the 19 patients enrolled in this cohort; two patients came off treatment prior 
to first restaging due to withdrawal of consent and patient choice. The third patient had not reached the 9- week response 
assessment period. Two patients with 100% reduction in target lesions were considered as irPR as irCR could not be confirmed 
in one patient at the time of data cut- off and the presence of non- target lesion in the other patient precluded the assignment 
of irCR. Two patients with unconfirmed irPR were considered as irSD for the analysis as one patient withdrew consent from 
the study and another patient came off treatment due to toxicity prior to the date of data cut- off. In the adrenocortical cancer 
cohort, response data is not shown for two of the 15 patients enrolled in this cohort as they came off treatment prior to first 
restaging due to toxicity and PI choice. In the carcinoma of unknown primary cohort, response data is not shown for nine 
patients as two patients came off treatment prior to first restaging due to withdrawal of consent and seven patients had not 
reached the 9- week response assessment period. In the paraganglioma–pheochromocytoma cohort, response data is not 
shown for one patient who had not reached the 9- week response assessment period. One another patient with 56% decrease 
in the size of the target lesions was considered to have irPD due to the presence of new non- target lesions in the liver, which 
was confirmed in the subsequent scan. CR, complete response; ir, immune- related; PD, progressive disease; PR, partial 
response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
months. In addition, four patients had irSD ≥4 months, 
representing a CBR of 54% (95% CI, 25% to 81%).
In the cohort of patients with paraganglioma- 
pheochromocytoma, nine patients received at least one 
dose of pembrolizumab. The NPR at 27 weeks was 43% 
(three of seven evaluable patients; 95% CI, 10% to 82%). 
At the time of data cut- off, one patient had not reached the 
9- week response assessment period. Of the eight patients 
evaluable for response, six patients had irSD, and all of 
them had disease control for ≥4 months, representing a 
CBR of 75% (95% CI, 35% to 97%). Three of these six 
patients were still continuing treatment at 5·0, 18·5, and 
19·8 months after treatment initiation. One patient with 
56% decrease in target lesions was considered to have 
irPD due to the presence of new non- target lesions in the 
liver, which was confirmed in the subsequent scan.
Responses were also seen in other cohorts. irPR was 
seen in penile carcinoma cohort (n=1) and other rare 
histologies (n=4; cancer of the orbit, pituitary carcinoma, 
alveolar soft part sarcoma, and epithelioid neoplasm of 
the dermis). In addition, irSD ≥4 months was seen in 
the cohorts for vascular sarcoma (n=2), germ cell tumor 
(n=3), and other rare histologies (n=6; patients with gran-
ulosa cell tumor of the ovary (n=2), mesothelioma in the 
testicle, intracranial meningioma, sclerosing epithelioid 
fibrosarcoma, and neuroblastoma (n=1 each)).
Six of 34 patients who continued treatment after an 
initial assessment of PD by RECIST V.1.1 derived benefit. 
Two of them with irPR as their best overall response (75% 
decrease and 73% decrease) continue to receive treat-
ment at week 91 and 75 since treatment initiation. The 
other four patients had 41% decrease, 38% decrease, 
26% decrease, and 16% decrease as best overall response 
before discontinuing treatment at week 42, 25, 32, and 25 
respectively.
Of the 127 patients who received at least one dose of 
pembrolizumab, 119 (94%) experienced at least one 
treatment- emergent adverse event (online supplemen-
tary table 1). A total of 146 treatment- related adverse 
events (TRAEs) of any grade occurred in 66 (52%) 
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Figure 2 Kinetics of tumor measurement during treatment with pembrolizumab. Percentage changes in tumor measurements 
from baseline per irRECIST during the course of treatment with pembrolizumab by PD- L1 expression levels are shown for all the 
patients represented in figure 1. Panel (A) squamous cell carcinoma of the skin. Panel (B) adrenocortical carcinoma. Panel (C) 
carcinoma of unknown primary and Panel (D) paraganglioma–pheochromocytoma. Of the patients represented in figure 1, five 
patients are not represented in figure 2. Three patients had clinical progression of disease (squamous cell carcinoma of the skin 
(n=1) and carcinoma of unknown primary (n=2)) and two patients had no measurable disease (squamous cell carcinoma of the 
skin (n=1) and carcinoma of unknown primary (n=2)). irRECIST, immune- related Response Evaluation Criteria in Solid Tumors; 
PD- L1, programmed cell death- ligand 1.
patients (table 3). Sixteen TRAEs grade ≥3 occurred in 
12 (9%) patients. The most common TRAEs (occurred 
in ≥10% of the patients) were fatigue (n=25), maculo-
papular rash (n=17), and hypothyroidism (n=14). The 
most common TRAEs of grade ≥3 were anemia (n=4), 
pneumonitis (n=3), and increased alanine aminotrans-
ferase level (n=2). Six deaths (5%) were reported during 
the study, five due to PD and one due to acute kidney 
injury secondary to sepsis; none were treatment- related. 
Treatment- related irAEs of any grade occurred in 24 
(19%) patients; treatment- related irAEs were grade ≥3 
in eight (6%) patients (online supplementary table 2). 
The most common irAEs were hypothyroidism (n=14), 
pneumonitis (n=4), and hyperthyroidism (n=4). The only 
irAE grade ≥3 that occurred in more than one patient was 
pneumonitis.
PD- L1 membrane expression and presence of TILs 
were assessed in tumor samples from 105 patients (online 
supplementary table 3). Of these 105 patients, 91 had 
data on primary endpoint. Seventy- four of the 91 (81%) 
patients had a PD- L1 H- score ≤42·5, while 17 had a score 
>42·5. A higher proportion of the patients with a PD- L1 
H- score >42·5 were alive and progression free at 27 weeks 
(8/17 (47%), compared with 15/74 (20%) for H- score 
≤42·5; p=0·02). TIL score was not associated with the 
primary endpoint (p=0·99). Three of the four (75%) 
patients with a TIL score of 0, eight of the 42 (19%) with 
a TIL score of 1, five of the 22 (23%) with a TIL score of 
2, and seven of the 23 (30%) with a TIL score of 3 were 
alive and progression free at 27 weeks.
dIsCussIon
The objective of this histology- independent, phase 2 study 
was to identify promising signals of antitumor activity of 
pembrolizumab across different rare cancers. As delayed 
response is characteristically seen with immunothera-
peutic agents, landmark survival estimates have been 
widely used for reporting treatment outcomes with immu-
notherapy as conventional endpoints may not be ideal.14 15 
In our study as imaging was performed at baseline and at 
9- week intervals, the primary endpoint NPR at 27 weeks 
allowed us to observe the tumor for three imaging cycles, 
which would give us a fair estimate of the drug activity 
that can be followed up in later studies. Antitumor activity 
was observed in cohorts of patients with SCC of the skin, 
ACC, CUP, and paraganglioma- pheochromocytoma.
SCC of the skin accounts for 20% of non- melanoma 
skin cancers.16 While surgical excision is curative in local-
ized SCC of the skin, no effective treatment was available 
for locally advanced or metastatic disease,17 until cemi-
plimab, a PD-1 inhibitor, was recently FDA- approved 
for this indication.18 Though ORR of 47% was reported 
in patients with metastatic SCC of the skin treated with 
cemiplimab, 68% of patients either had received no prior 
systemic therapy or only one line of prior systemic therapy 
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Table 3 Treatment- related adverse events in 127 patients 
treated with pembrolizumab
Adverse event










9 (7) 1 (1)
Alanine aminotransferase 
increased
8 (6) 2 (2)
Anemia 8 (6) 4 (3)
Arthralgia 6 (5)
Alkaline phosphatase increased 5 (4) 1 (1)
Hyperthyroidism 4 (3)
Nausea 4 (3)
Pneumonitis 4 (3) 3 (2)
Diarrhea 3 (2) 1 (1)
Pruritus 3 (2)
Dyspnea 2 (2)
Edema, limbs 2 (2)
Hyperglycemia 2 (2) 1 (1)
Myalgia 2 (2)
Peripheral sensory neuropathy 2 (2)
Skin and subcutaneous tissue 
disorders—Other, specify*
2 (2)
Skin infection 2 (2)
Arthritis 1 (1) 1 (1)
Blood bilirubin increased 1 (1)
Colitis 1 (1) 1 (1)
Creatinine increased 1 (1)
Dry skin 1 (1)
Dysgeusia 1 (1)
Genital edema 1 (1)
Hyponatremia 1 (1)
Thyroiditis 1 (1)
Mucositis, oral 1 (1)
Tremor due to subacute 
progressive cerebellar 
dysfunction
1 (1) 1 (1)
*Rash other than maculopapular rash
with curative intent. Interim results from two other phase 
2 studies of pembrolizumab in patients with SCC of the 
skin have been reported. An ORR of 42% at 15 weeks has 
been reported with pembrolizumab as first line of therapy 
in 17 evaluable patients with unresectable SCC of skin.19 
In another study, an ORR of 40% has been reported in 
10 patients with metastatic SCC of skin, majority of whom 
have not received prior systemic therapy.20 Thus, find-
ings from our study (ORR of 31% and CBR of 38%) is 
noteworthy given that all of our patients had refractory 
disease and 88% of them had received ≥1 prior systemic 
therapy. Studies estimate that SCC of the skin causes a 
similar number of deaths to melanoma.21 Given that the 
incidence of SCC of the skin has risen dramatically, by 
up to 200%, in the past three decades in the USA,16 22 
the mortality rate is likely to rise as well, indicating that 
an effective therapeutic option is needed for this under-
served population. Therefore, the above findings indi-
cate that pembrolizumab may be a potential therapeutic 
option for patients with SCC of the skin, both in treat-
ment naïve and refractory setting.
ACC is an orphan endocrine malignancy character-
ized by a poor prognosis and limited response to chemo-
therapy.23 Most patients with ACC experience rapid 
disease progression, and the median overall survival 
(OS) remains dismal at 9 months for patients with stage 
IV disease.24 Mitotane, the only FDA- approved agent for 
ACC, is often used in combination with etoposide, doxo-
rubicin, and cisplatin.25 However, treatment with mito-
tane and chemotherapy is associated with considerable 
toxicity that frequently makes it difficult for patients to 
continue therapy. Data about immunotherapy in ACC 
are limited, despite reported PD- L1 expression in 11% 
of 28 surgically resected primary ACC tumors.26 Recently, 
6% ORR was reported in patients treated with avelumab, 
but almost half of that study’s subjects had concomitant 
therapy with mitotane, which clouds the interpretation 
of the efficacy of avelumab.27 In this context, the ORR 
of 15% and CBR of 54% in our study using single- agent 
pembrolizumab are clinically meaningful. Given that all 
therapies for metastatic ACC are considered palliative at 
best,23 the NPR of 31% in our ACC cohort is encouraging.
CUP accounts for 2% of all solid cancers and is asso-
ciated with poor prognosis. The 2- year survival rate has 
been reported to be less than 20% with empiric platinum- 
based combination regimens.28 In the absence of stan-
dard of care or FDA- approved agents to treat CUP, there 
is a critical and unmet need to develop novel therapeutic 
strategies to treat CUP. Recently, 22·5% of 389 patients 
with CUP were reported to have PD- L1–positive tumor 
cells, 58·7% PD-1–positive TILs, and 11·8% a high total 
mutation load.29 Despite the presence of these prom-
ising indicators of response, with the exception of a few 
case reports,30–32 the role of checkpoint inhibitors has 
not been investigated in patients with CUP. As such, the 
results from our study showing early signs of clinical 
activity resulting in an NPR of 33% at 27 weeks, ORR 
of 23%, and CBR of 54% are encouraging and must be 
explored further.
Metastatic pheochromocytomas and paragangliomas 
are rare neuroendocrine tumors associated with poor 
prognosis.33 High- specific- activity meta- iodine benzyl 
guanidine (MIBG) is the only FDA- approved systemic 
therapy for the treatment of these patients, and it is only 
effective for the roughly half of patients with MIBG- avid 
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tumors.34 Treatment with the chemotherapeutic agents 
cyclophosphamide, vincristine, and dacarbazine is at 
best palliative and is associated with a clinical benefit 
in approximately 37% of patients.35 Several antiangio-
genic agents, such as sunitinib, pazopanib, axitinib, and 
cabozantinib, are under investigation. Given that PD- L1/
PD- L2 were expressed in 50% of the tumors surgically 
removed,36 NPR of 43% and CBR of 75% in our study, 
provides a rationale for the development of pembroli-
zumab for these tumors.
Evaluation of the efficacy of immunotherapeutic agents 
remains a challenge, as the transient increase in the size 
of the tumor and/or the development of new lesions 
due to the inflammatory response (also termed pseu-
doprogression) may be misdiagnosed as PD by conven-
tional RECIST V.1.1, the only imaging assessment criteria 
accepted by the FDA for drug approval.37 In our study, 
adaptations made to RECIST V.1.1 allowed 34 patients to 
continue treatment beyond the first assessment of PD by 
RECIST V.1.1, six (18%) of whom derived benefit. These 
patients would have been removed prematurely from the 
study by RECIST V.1.1. Nevertheless, for patients with true 
PD, such a wait to confirm PD delays switching to more 
effective therapy and exposes these patients to an unnec-
essary risk of toxicity. Therefore, it is critical to develop 
a biomarker to distinguish in real time between patients 
with atypical responses and those with true PD.
Currently, there are no validated markers of response 
to treatment, and the predictive potential of PD- L1 as a 
biomarker is much debated. Different cut- off values such 
as ≥1%, ≥5%, ≥10% and≥50% have been used in different 
studies as summarized by Diggs and Hsueh38 to stratify 
patients by PD- L1 expression. In the absence of a stan-
dardized cut- off value for assessing PD- L1- positivity, we 
had used recursive partitioning analysis to identify the 
cut- off value for PD- L1 H- score. Therefore, our finding 
that a higher proportion of patients with a PD- L1 H- score 
≥42·5 were alive and progression free at 27 weeks should 
be considered preliminary. Nevertheless, given that 
pembrolizumab has been approved for first- line treat-
ment of advanced non- small cell lung cancer in patients 
with high PD- L1 expression according to an FDA‐
approved test in the absence of EGFR or ALK molecular 
alterations,39 PD- L1 expression likely reflects an immune- 
active tumor milieu that should be investigated further. 
Contrary to the conventional belief that the presence of 
TILs is a favorable prognostic indicator of response to 
treatment with checkpoint inhibitors, in our study TIL 
score was not associated with NPR at 27 weeks. Though 
unexplained, similar findings have been reported in a 
phase 2 biomarker study in patients with unresectable 
melanoma treated with ipilimumab40 and in patients 
with melanoma, non- small cell lung cancer, renal cell 
carcinoma, colorectal carcinoma, or castration- resistant 
prostate cancer treated with nivolumab.41 One possible 
explanation could be the presence of other immuno-
suppressive factors such as indoleamine 2,3- dioxygenase 
(IDO) and arginase in the tumor microenvironment. 
Thus, additional investigations are needed to iden-
tify immune correlates of response to treatment with 
pembrolizumab.
The safety profile of pembrolizumab in patients with 
advanced rare cancer is consistent with that previously 
reported for other common cancers, such as melanoma 
and non- small cell lung cancer.
We acknowledge that our study has a few limitations. 
First, the small sample size of the tumor- specific cohorts 
precluded us from making inferences applicable to all 
rare cancers. Second, the site from which the tissue was 
procured (primary vs metastatic) for biomarker assess-
ment may have influenced the immune marker levels. 
Third, the differences in antitumor activity between 
different cancers is likely a reflection of differences in the 
tumor microenvironment. Nonetheless, because these 
are rare tumors, the period until the final analysis may 
be prolonged. Considering the poor prognosis associ-
ated with the lack of evidence- based treatment options 
for many of these tumor types, we chose to report the 
results from the interim analysis to inform the scientific 
community. In conclusion, the current study provides 
early indications of antitumor activity of pembrolizumab 
in four tumor- specific cohorts of patients with SCC of 
the skin, ACC, CUP, and metastatic pheochromocy-
toma–paraganglioma. This finding is significant given 
that these patients had experienced disease progression 
while on another treatment within the previous 6 months 
or had no standard- of- care therapies available. Findings 
from our study support further investigation to confirm 
the clinical activity of pembrolizumab in advanced rare 
cancers and to identify immune signatures predictive of 
response to treatment.
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